|
77
|
279
|
4c4hA |
Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase mps1 |
|
88
|
280
|
4c4fA |
Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase mps1 |
|
74
|
279
|
4c4jA |
Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase mps1 |
|
78
|
279
|
4c4iA |
Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase mps1 |
|
82
|
279
|
4bi0A |
Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor |
|
77
|
279
|
4bhzA |
Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor |
|
82
|
279
|
4bi1A |
Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor |
|
127
|
409
|
4azfA |
Human dyrk2 in complex with leucettine l41 |
|
78
|
279
|
4bi2A |
Scaffold focused virtual screening: prospective application to the discovery of ttk inhibitor |
|
118
|
350
|
4azeA |
Human dyrk1a in complex with leucettine l41 |
|
58
|
141
|
4b94A |
Crystal structure of human mps1 tpr domain |
|
73
|
280
|
3wyxA |
Crystal structure of human mps1 catalytic domain in complex with 6-((3-(cyanomethoxy)-4-(1-methyl-1h-pyrazol-4-yl)phenyl)amino)-2-(cyclohexylamino)nicotinonitrile |
|
72
|
279
|
3wzkA |
Crystal structure of human mps1 catalytic domain in complex with n-cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3-yl)benzamide |
|
73
|
279
|
3wzjA |
Crystal structure of human mps1 catalytic domain in complex with 4-(6-(cyclohexylamino)-8-(((tetrahydro-2h-pyran-4-yl)methyl)amino)imidazo[1,2-b]pyridazin-3-yl)-n-cyclopropylbenzamide |
|
72
|
280
|
3wyyA |
Crystal structure of human mps1 catalytic domain in complex with (e)-3-(4-((6-(((3s,5s,7s)-adamantan-1-yl)amino)-4-amino-5-cyanopyridin-2-yl)amino)-2-(cyanomethoxy)phenyl)-n-(2-methoxyethyl)acrylamide |
|
70
|
280
|
3w1fA |
Crystal structure of human mps1 catalytic domain in complex with 5-(5-ethoxy-6-(1-methyl-1h-pyrazol-4-yl)-1h-indazol-3-yl)-2-methylbenzenesulfonamide |
|
71
|
280
|
3vquA |
Crystal structure of human mps1 catalytic domain in complex with 4-[(4-amino-5-cyano-6-ethoxypyridin-2- yl)amino]benzamide |
|
114
|
351
|
3rawA |
Crystal structure of human cdc-like kinase 3 isoform in complex with leucettine l41 |
|
112
|
328
|
5x8iA |
Crystal structure of human clk1 in complex with compound 25 |
|
108
|
347
|
5unpA |
Structure of cdc2-like kinase 2 (clk2) in complex with compound t-025 [n2-methyl-n4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine] |
|
59
|
261
|
5t2fA |
Structure of the fha1 domain of rad53 bound to the brct domain of dbf4 |
|
71
|
260
|
5t2sA |
Structure of the fha1 domain of rad53 bound simultaneously to the brct domain of dbf4 and a phosphopeptide. |
|
80
|
283
|
5o91A |
Crystal structure of human mps1 (ttk) c604w mutant in complex with cpd-5 |
|
82
|
287
|
5nttA |
Crystal structure of human mps1 (ttk) c604y mutant in complex with nms-p715 |
|
82
|
279
|
5n87A |
Ttk kinase domain in complex with ntrc 0066-0 |
|
78
|
279
|
5n7vA |
Ttk kinase domain in complex with mpi-0479605 |
|
116
|
348
|
5a3xA |
Dyrk1a in complex with hydroxy benzothiazole fragment |
|
78
|
280
|
4zegA |
Crystal structure of ttk kinase domain in complex with a pyrazolopyrimidine inhibitor |
|
74
|
279
|
5ei2A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
78
|
286
|
5ap7A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
79
|
281
|
5ap1A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
84
|
279
|
5ei6A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
74
|
279
|
5eh0A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
72
|
280
|
5ap5A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
83
|
279
|
5ehoA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
76
|
279
|
5ap3A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
78
|
280
|
5ap0A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
79
|
280
|
5ehyA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
76
|
279
|
5ap2A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
77
|
280
|
5ap4A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
84
|
280
|
5ei8A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
72
|
282
|
5ehlA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
82
|
279
|
5ap6A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
119
|
348
|
4yllA |
Crystal structure of dyrk1aa in complex with 10-bromo-substituted 11h-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t |
|
117
|
348
|
4ylkA |
Crystal structure of dyrk1a in complex with 10-chloro-substituted 11h-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s |
|
120
|
347
|
4yljA |
Crystal structure of dyrk1a in complex with 10-iodo-substituted 11h-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j |
|
116
|
348
|
5aikA |
Human dyrk1a in complex with ldn-211898 |
|
77
|
304
|
4pdpA |
Crystal structure of rad53 kinase domain and scd2 |
|
69
|
300
|
4pdsA |
Crystal structure of rad53 kinase domain and scd2 in complex with amppnp |
|
112
|
347
|
4nctA |
Human dyrk1a in complex with pkc412 |
